930 related articles for article (PubMed ID: 24052129)
1. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
2. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S; Chan T; Sami A; El-Gayed A; Xiang J
Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
[TBL] [Abstract][Full Text] [Related]
4. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
5. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.
Chen Y; Xie Y; Chan T; Sami A; Ahmed S; Liu Q; Xiang J
Cancer Gene Ther; 2011 Jul; 18(7):489-99. PubMed ID: 21566669
[TBL] [Abstract][Full Text] [Related]
7. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
8. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
9. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
12. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
16. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
17. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
18. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
20. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
Sotiriadou NN; Kallinteris NL; Gritzapis AD; Voutsas IF; Papamichail M; von Hofe E; Humphreys RE; Pavlis T; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2007 May; 56(5):601-13. PubMed ID: 16960693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
